Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0R0SP
|
|||
Former ID |
DIB015758
|
|||
Drug Name |
LIPO-5
|
|||
Synonyms |
HIV vaccine (lipoprotein), ANRS/Aventis Pasteur
Click to Show/Hide
|
|||
Drug Type |
Vaccine
|
|||
Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 2 | [1] | |
Company |
Sanofi Pasteur
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Human immunodeficiency virus GAG protein (HIV gag) | Target Info | . | [2] |
Human immunodeficiency virus Negative factor (HIV nef) | Target Info | . | [2] | |
Reactome | Uncoating of the HIV Virion | |||
Budding and maturation of HIV virion | ||||
Integration of provirus | ||||
Early Phase of HIV Life Cycle | ||||
Minus-strand DNA synthesis | ||||
Plus-strand DNA synthesis | ||||
2-LTR circle formation | ||||
Binding and entry of HIV virion | ||||
Membrane binding and targetting of GAG proteins | ||||
Assembly Of The HIV Virion | ||||
Integration of viral DNA into host genomic DNA | ||||
Autointegration results in viral DNA circles | ||||
APOBEC3G mediated resistance to HIV-1 infection | ||||
Vpr-mediated nuclear import of PICs | ||||
WikiPathways | Host Interactions of HIV factors | |||
HIV Life Cycle |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01492985) Lipopeptide Immunisation With GTU-multiHIV Trial. U.S. National Institutes of Health. | |||
REF 2 | HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.